Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


April 19, 2015 7:38 AM ET

Pharmaceuticals

Company Overview of Ritter Pharmaceuticals, Inc.

Company Overview

Ritter Pharmaceuticals, Inc. develops novel therapeutic products, which modulate the human gut microbiome to treat inflammatory, gastrointestinal, and metabolic diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which is under development for the reduction of symptoms associated with lactose intolerance. RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. RP-G28 has been studied in a Phase 2a clinical trial. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in...

1801 Century Park East

Suite 1820

Los Angeles, CA 90067

United States

Founded in 2004

5 Employees

Phone:

310-203-1000

Fax:

310-919-1600

Key Executives for Ritter Pharmaceuticals, Inc.

Chief Executive Officer and Director
Age: 54
Founder, President and Director
Chairman and Chief Strategic Officer
Chief Financial Officer
Board Observer
Compensation as of Fiscal Year 2014.

Ritter Pharmaceuticals, Inc. Key Developments

Ritter Pharmaceuticals, Inc. Appoints Paul V. Maier as a Board of Directors

Ritter Pharmaceuticals, Inc. appointed Paul V. Maier as a Board of Directors. Mr. Maier will chair the company’s audit committee. Mr. Maier served for five years as the Chief Financial Officer of life sciences company Sequenom, Inc. He previously served for 15 years as the Senior Vice President and Chief Financial Officer of Ligand Pharmaceuticals, Inc. Mr. Maier currently serves on the Boards of Directors of International Stem Cell Corporation, Apricus Biosciences, MabVax Therapeutics and Biological Dynamics.

Ritter Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt

Ritter Pharmaceuticals, Inc. filed its S-1 on Mar 23, 2015 for the period ending Dec 31, 2014. In this report its auditor, Mayer Hoffman McCann P.C., gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Ritter Pharmaceuticals, Inc. Appoints Matthew W. Foehr to Board of Directors

Ritter Pharmaceuticals, Inc. announced the appointment of Matthew W. Foehr to the Board of Directors. Mr. Foehr is President and Chief Operating Officer of Ligand Pharmaceuticals and his appointment expands Ritter's Board membership to five Directors. He brings Ritter significant experience in many areas that are critical to business success, including clinical, operations and commercial. Mr. Foehr has more than 20 years of experience in the pharmaceutical industry, having managed global operations and various research and development programs.

Similar Private Companies By Industry

Company Name Region
Simply H, LLC United States
Pharmalab Enterprises, Inc. United States
Entegrion, Inc. United States
Colloral LLC United States
Ruga Corporation United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
December 4, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Ritter Pharmaceuticals, Inc., please visit www.ritterpharmaceuticals.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.